logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9321728 B1

PDFFull Text
Date of Patent:
Apr. 26, 2016

Filed:

Apr. 25, 2013

Beta-alanine derivatives, pharmaceutically acceptable salts thereof, and pharmaceutical composition comprising same as active ingredient

Applicants:

Korea Research Institute of Chemical Technology, Daejeon, KR;

Handok Pharmaceuticals Co., Ltd., Seoul, KR;

Inventors:

Jin Hee Ahn, Daejeon, KR;

H. S. Pagire, Daejeon, KR;

Sang Dal Rhee, Daejeon, KR;

Ki Young Kim, Daejeon, KR;

Won Hoon Jung, Daejeon, KR;

Myung-Ae Bae, Daejeon, KR;

Jin Sook Song, Daejeon, KR;

Kwang-Rok Kim, Daejeon, KR;

Hyun Jung Kwak, Daejeon, KR;

Assignees:

KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY, Daejeon, KR;

HANDOK PHARMACEUTICALS CO., LTD., Seoul, KR;

Attorney:

Ladas & Parry LLP

Primary Examiner:

Laura L Stockton

Int. Cl.
CPC ...
C07D 263/32 (2006.01); C07D 231/12 (2006.01); C07D 209/20 (2006.01); C07D 271/06 (2006.01); C07D 277/30 (2006.01); C07D 261/08 (2006.01); C07D 213/56 (2006.01); C07D 239/26 (2006.01); C07D 213/82 (2006.01); A61K 45/06 (2006.01); A61K 31/421 (2006.01); A61K 31/415 (2006.01); A61K 31/27 (2006.01); C07C 237/12 (2006.01); A61K 31/216 (2006.01); A61K 31/403 (2006.01); A61K 31/167 (2006.01); C07C 271/22 (2006.01); C07D 231/14 (2006.01); C07D 417/12 (2006.01); C07D 261/10 (2006.01); C07D 263/34 (2006.01); C07C 237/04 (2006.01); C07C 237/22 (2006.01); C07D 277/56 (2006.01); C07D 209/42 (2006.01);
U.S. Cl.
CPC ...
C07D 213/82 (2013.01); A61K 31/167 (2013.01); A61K 31/216 (2013.01); A61K 31/27 (2013.01); A61K 31/403 (2013.01); A61K 31/415 (2013.01); A61K 31/421 (2013.01); A61K 45/06 (2013.01); C07C 237/04 (2013.01); C07C 237/12 (2013.01); C07C 237/22 (2013.01); C07C 271/22 (2013.01); C07D 209/20 (2013.01); C07D 209/42 (2013.01); C07D 213/56 (2013.01); C07D 231/12 (2013.01); C07D 231/14 (2013.01); C07D 239/26 (2013.01); C07D 261/08 (2013.01); C07D 261/10 (2013.01); C07D 263/32 (2013.01); C07D 263/34 (2013.01); C07D 271/06 (2013.01); C07D 277/30 (2013.01); C07D 277/56 (2013.01); C07D 417/12 (2013.01); C07B 2200/07 (2013.01); C07C 2101/14 (2013.01);
Abstract

The present invention relates to a beta-alanine derivative, pharmaceutically acceptable salts thereof, and a pharmaceutical composition including the same as an active ingredient. The novel beta-alanine derivative and pharmaceutically acceptable salts thereof according to the present invention may effectively inhibit the activity of DGAT1, which is an enzyme serving as a catalyst in the final step of the synthesis of neutral lipids, to thereby be effectively used as a pharmaceutical composition for preventing or treating various lipid metabolism-related disorders selected from the group consisting of obesity, dyslipidemia, fatty liver, insulin resistance syndrome, and hepatitis.

Find Patent Forward Citations

Loading…